Ventyx Biosciences (VTYX) Competitors $2.70 +0.06 (+2.08%) As of 01:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. OCS, ORIC, NUVB, SION, NAGE, VALN, CRMD, IOVA, PROK, and NRIXShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Oculis (OCS), Oric Pharmaceuticals (ORIC), Nuvation Bio (NUVB), Sionna Therapeutics (SION), Niagen Bioscience (NAGE), Valneva (VALN), CorMedix (CRMD), Iovance Biotherapeutics (IOVA), ProKidney (PROK), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Its Competitors Oculis Oric Pharmaceuticals Nuvation Bio Sionna Therapeutics Niagen Bioscience Valneva CorMedix Iovance Biotherapeutics ProKidney Nurix Therapeutics Oculis (NASDAQ:OCS) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation. Which has more volatility and risk, OCS or VTYX? Oculis has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Is OCS or VTYX more profitable? Ventyx Biosciences has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. Ventyx Biosciences' return on equity of -48.89% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-13,788.70% -92.95% -70.03% Ventyx Biosciences N/A -48.89%-44.87% Does the media favor OCS or VTYX? In the previous week, Oculis had 14 more articles in the media than Ventyx Biosciences. MarketBeat recorded 14 mentions for Oculis and 0 mentions for Ventyx Biosciences. Oculis' average media sentiment score of 0.86 beat Ventyx Biosciences' score of -0.80 indicating that Oculis is being referred to more favorably in the media. Company Overall Sentiment Oculis Positive Ventyx Biosciences Negative Do institutionals and insiders have more ownership in OCS or VTYX? 22.3% of Oculis shares are owned by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are owned by institutional investors. 14.5% of Ventyx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, OCS or VTYX? Oculis has higher revenue and earnings than Ventyx Biosciences. Oculis is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$780K1,005.30-$97.43M-$2.64-6.80Ventyx BiosciencesN/AN/A-$135.12M-$1.68-1.61 Do analysts prefer OCS or VTYX? Oculis presently has a consensus price target of $35.67, suggesting a potential upside of 98.59%. Ventyx Biosciences has a consensus price target of $7.50, suggesting a potential upside of 177.26%. Given Ventyx Biosciences' higher possible upside, analysts plainly believe Ventyx Biosciences is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryVentyx Biosciences beats Oculis on 9 of the 15 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$192.97M$3.10B$5.82B$9.71BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-1.6121.0530.9025.97Price / SalesN/A400.98469.81120.77Price / CashN/A43.0937.1558.38Price / Book0.928.089.116.37Net Income-$135.12M-$54.72M$3.26B$265.56M7 Day Performance-4.42%2.17%1.85%1.71%1 Month Performance-10.43%7.13%4.86%1.05%1 Year Performance37.31%12.70%31.15%20.94% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences2.4753 of 5 stars$2.71+2.1%$7.50+177.3%+35.2%$192.97MN/A-1.6130OCSOculis3.2022 of 5 stars$17.97-1.3%$35.33+96.6%+49.1%$795.09M$780K-6.812News CoverageEarnings ReportAnalyst ForecastORICOric Pharmaceuticals4.7546 of 5 stars$9.20-0.4%$18.57+101.9%-1.2%$787.47MN/A-4.9280NUVBNuvation Bio2.2997 of 5 stars$2.24-2.8%$7.33+228.1%-2.3%$782.60M$7.87M-3.5560SIONSionna Therapeutics1.9269 of 5 stars$20.03+13.4%$38.50+92.2%N/A$779.68MN/A0.0035NAGENiagen Bioscience1.3253 of 5 stars$9.82+0.9%$13.42+36.7%N/A$776M$99.60M46.76120VALNValneva2.5752 of 5 stars$8.50-6.7%$15.50+82.4%+41.3%$775.21M$183.52M-7.14700Trending NewsAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeCRMDCorMedix2.6396 of 5 stars$10.07-2.5%$16.71+66.0%+170.7%$771.12M$43.47M13.4330IOVAIovance Biotherapeutics4.8405 of 5 stars$1.97-6.6%$11.90+504.1%-78.5%$763.51M$164.07M-1.60500Analyst ForecastShort Interest ↓PROKProKidney3.7203 of 5 stars$2.26-12.7%$6.25+176.5%-2.9%$758.09M$80K-3.773News CoverageShort Interest ↓NRIXNurix Therapeutics2.3985 of 5 stars$9.65-1.9%$28.87+199.1%-59.6%$752.26M$54.55M-3.70300 Related Companies and Tools Related Companies Oculis Competitors Oric Pharmaceuticals Competitors Nuvation Bio Competitors Sionna Therapeutics Competitors Niagen Bioscience Competitors Valneva Competitors CorMedix Competitors Iovance Biotherapeutics Competitors ProKidney Competitors Nurix Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access